



February 23th, 2021
BioComo Inc.

BioComo and Mie University announce initiation of joint development of vaccines for SARS-CoV-2 variants using BC-PIV vector

We are pleased to announce that BioComo Inc. and Mie University jointly initiated the production of nasal vaccines using BC-PIV vector against recently reported variants of SARS-CoV-2.

We plan to create multiple candidates of novel intranasal vaccine of BC-PIV / SARS-CoV-2 Variant. Among multiple variants reported, spike protein gene mutation is considered to have a most important role in severity and transmissibility of infection, which will be optimized to construct BC-PIV based vaccines. Vaccine candidates will be available in about 3 weeks, to be followed by in vitro and in vivo testing to evaluate their efficacy.

【About BioComo Inc.】

Privately held biotech company, founded in May 2008

Head Office : 1325 Komono, Mie-gun, Mie, Japan 510-1233

Executive Member:

Masayuki Fukumura, Ph.D., Founder, CEO & CSO

Hiromu Ozaki, Board, BD

Hiroki Hideshima, Board, CFO

Mitsuhiro Fujita, Board

URL: <http://biocomo.jp/>

Category of Business: Vaccines against infectious diseases and
Immunomodulators for solid tumors

Contact: info@biocomo.jp